UY29198A1 - Derivados sustituidos de quinazolinona y derivados sustituidos de quinazolina-2, 4-diona, composiciones conteniéndolos, procedimientos de preparación y aplicaciones - Google Patents

Derivados sustituidos de quinazolinona y derivados sustituidos de quinazolina-2, 4-diona, composiciones conteniéndolos, procedimientos de preparación y aplicaciones

Info

Publication number
UY29198A1
UY29198A1 UY29198A UY29198A UY29198A1 UY 29198 A1 UY29198 A1 UY 29198A1 UY 29198 A UY29198 A UY 29198A UY 29198 A UY29198 A UY 29198A UY 29198 A1 UY29198 A1 UY 29198A1
Authority
UY
Uruguay
Prior art keywords
derivatives
quinazolinona
quinazolina
diona
applications
Prior art date
Application number
UY29198A
Other languages
English (en)
Inventor
Berdini Valerio
Saxty Gordon
Woodhead Steven John
Wyatt Paul Graham
Boyle Robert George
Sore Hannah Fiona
Walker David Winter
Collins Ian
Marinus Leendert Verdonk
John Caldwell
Original Assignee
Cancer Rec Tech Ltd
Cancer Res Inst Royal
Astex Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0424742A external-priority patent/GB0424742D0/en
Application filed by Cancer Rec Tech Ltd, Cancer Res Inst Royal, Astex Therapeutics Ltd filed Critical Cancer Rec Tech Ltd
Publication of UY29198A1 publication Critical patent/UY29198A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

La invención proporciona un compuesto de fórmula (I) o una sal, solvato, tautómero o N-óxido del mismo para su uso en el tratamiento o profilaxis de un estado de enfermedad o trastorno mediado por la proteína quinasa A y/o la proteína quinasa B; en donde el anillo Q, J2 -J1; G, E, A, R4, R4a, R1, R2, y R3 son como fueron definidos en l memoria descriptiva y en las reivindicaciones.
UY29198A 2004-11-09 2005-11-08 Derivados sustituidos de quinazolinona y derivados sustituidos de quinazolina-2, 4-diona, composiciones conteniéndolos, procedimientos de preparación y aplicaciones UY29198A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62640304P 2004-11-09 2004-11-09
GB0424742A GB0424742D0 (en) 2004-11-09 2004-11-09 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
UY29198A1 true UY29198A1 (es) 2006-05-31

Family

ID=35695751

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29198A UY29198A1 (es) 2004-11-09 2005-11-08 Derivados sustituidos de quinazolinona y derivados sustituidos de quinazolina-2, 4-diona, composiciones conteniéndolos, procedimientos de preparación y aplicaciones

Country Status (6)

Country Link
US (1) US20080275029A1 (es)
EP (1) EP1814552A2 (es)
JP (1) JP2008519087A (es)
AR (1) AR053778A1 (es)
UY (1) UY29198A1 (es)
WO (1) WO2006051290A2 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007008926A1 (en) * 2005-07-11 2007-01-18 Aerie Pharmaceuticals, Inc. Isoquinoline compounds
US7618985B2 (en) 2005-12-08 2009-11-17 N.V. Organon Isoquinoline derivatives
US7893088B2 (en) * 2006-08-18 2011-02-22 N.V. Organon 6-substituted isoquinoline derivatives
CA2664335C (en) 2006-09-20 2014-12-02 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
US8455514B2 (en) * 2008-01-17 2013-06-04 Aerie Pharmaceuticals, Inc. 6-and 7-amino isoquinoline compounds and methods for making and using the same
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
CA2929545C (en) 2009-05-01 2019-04-09 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
RU2451010C1 (ru) * 2011-01-11 2012-05-20 Закрытое Акционерное Общество "Ива Фарм" Палладиево-медные катализаторы гомогенного селективного окисления тиольных групп, комбинация и композиция на их основе и способ терапевтического воздействия
EP3461484B9 (en) 2013-03-15 2021-06-09 Aerie Pharmaceuticals, Inc. Dimesylate salts of 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl, their combinations with prostaglandins and the use thereof in the treatment of ocular disorders
CN103524431B (zh) * 2013-09-24 2016-01-13 西安交通大学 3-苄基-4-喹唑啉酮类化合物及其合成方法和应用
DK3174868T3 (da) 2014-08-01 2021-11-08 Nuevolution As Forbindelser, der er aktive mod bromodomæner
AR103598A1 (es) 2015-02-02 2017-05-24 Forma Therapeutics Inc Ácidos bicíclicos[4,6,0]hidroxámicos como inhibidores de hdac
MX2020003488A (es) 2015-02-02 2022-05-24 Forma Therapeutics Inc Acidos 3-alquil-4-amido-biciclico [4,5,0] hidroxamicos como inhibidores de histona desacetilasas (hdac).
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
JP6832946B2 (ja) 2015-11-17 2021-02-24 アエリエ ファーマシューティカルズ インコーポレイテッド キナーゼ阻害剤およびその中間体の調製方法
EP3472131B1 (en) 2016-06-17 2020-02-19 Forma Therapeutics, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors
BR112019003945A2 (pt) 2016-08-31 2019-05-21 Aerie Pharmaceuticals, Inc. composições oftálmicas
CN110506037A (zh) 2017-03-31 2019-11-26 爱瑞制药公司 芳基环丙基-氨基-异喹啉酰胺化合物
MX2021000841A (es) 2018-07-26 2021-03-26 Domain Therapeutics Derivados de quinazolinona sustituidos y su uso como moduladores alostericos positivos de mglur4.
AU2019337703B2 (en) 2018-09-14 2023-02-02 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4281127A (en) * 1979-07-09 1981-07-28 Hoffmann-La Roche Inc. Trans-3-(4-oxo-4H-quinazolin-3-yl)-2-propenoic acid derivatives
UA73993C2 (uk) * 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
TW200301123A (en) * 2001-12-21 2003-07-01 Astrazeneca Uk Ltd New use

Also Published As

Publication number Publication date
WO2006051290A3 (en) 2006-09-14
EP1814552A2 (en) 2007-08-08
JP2008519087A (ja) 2008-06-05
WO2006051290A2 (en) 2006-05-18
AR053778A1 (es) 2007-05-23
US20080275029A1 (en) 2008-11-06

Similar Documents

Publication Publication Date Title
UY29198A1 (es) Derivados sustituidos de quinazolinona y derivados sustituidos de quinazolina-2, 4-diona, composiciones conteniéndolos, procedimientos de preparación y aplicaciones
UY29177A1 (es) Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
UY29610A1 (es) Aril-alquilaminas y heteroaril-alquilaminas como inhibidores de la quinasa proteínica
CL2017001426A1 (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
PE20211411A1 (es) Compuestos de anillo fusionado
UY37854A (es) Derivados de 3- (1-oxoisoindolin-2-il) piperidina-2,6-diona y usos de los mismos
UY29176A1 (es) Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen, métodos para su preparación y sus usos.
ECSP066886A (es) Compuestos y métodos para el tratamiento de dislipidemia
UY32462A (es) Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644
UY29199A1 (es) Derivados tiazol, composiciones que los contienen, procedimientos de preparación y aplicaciones
UY28936A1 (es) Grupo de compuestos benzoil-amino-heterociclilo y composiciones farmaceuticas que los comprenden, utiles para tratamiento de enfermedades mediadas por glucoquinasa (gq)
UY28526A1 (es) Miméticos de glucocorticoides, métodos de preparación composiciones farmacéuticas y usos de los mismos
ECSP055676A (es) Piperazinas heterocíclicas sustituidas para el tratamiento de la esquizofrenia
EA200401194A1 (ru) Миметики глюкокортикоидов, способы их получения, фармацевтические композиции и их применение
GT200600081A (es) Derivados de acetilenno
UY29458A1 (es) Heterociclos sustituidos y usos de los mismos
UY28885A1 (es) 4-fenilamino-quinazolin-6-il-amidas referencia cruzada a solicitud(es) relacionada(s)
PE20170666A1 (es) 2-(morfolin-4-il)-1,7-naftiridinas
CL2008002243A1 (es) Compuestos derivados de 2-pirazolamino-1,3,5-triazina, inhibidores de kinasa jak; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer.
UY30966A1 (es) Nuevos compuestos de adenina, sales farmaccuticamente aceptables, composiciones contenicndolos y aplicaciones
AR055613A1 (es) Formas cristalinas delta y epsilon de mesilato de imatinib
UY31430A1 (es) Derivados de piridina y pirazina -83
UY30779A1 (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa
UY28756A1 (es) Compuestos
GT200600138A (es) Compuestos sulfoximino-macrociclicos y sus sales, composiciones farmaceuticas que comprenden dichos compuestos, metodos de preparacion y usos de los mismos

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20160525